One clinical trial showed that etanercept, a TNF-α inhibitor, can attenuate disease in patients with severe COVID-19 by suppressing their systemic autoinflammatory responses (256), and patients with COVID-19 previously prescribed etanercept treatment did not develop severe COVID-19 (257). The gene discussed is TNF; the disease is COVID-19.